MFDS approves Adcetris to treat two types of lymphoma

Published: 2013-05-22 06:57:00

Updated: 2013-05-22 06:57:00

Takeda Korea said Monday that the Ministry of Food and Drug Safety (MFDA) approved Adcetris (brentuximab vedotin) to treat Hodgkin lymphoma (HL) and a rare lymphoma known as systemic anaplastic large cell lymphoma (ALCL).

Lymphomas are cancers of the lymphatic system. Adcetris is an antibody-d...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK